The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 31, 2026

Filed:

Oct. 01, 2020
Applicants:

Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;

Université DE Lille, Lille, FR;

Institut Pasteur DE Lille, Lille, FR;

Centre Hospitalier Régional Universitaire DE Lille, Lille, FR;

Inventors:

Sophie Susen, Lille, FR;

Delphine Corseaux, Lille, FR;

Yoann Sottejeau, Lille, FR;

Mickael Rosa, Lille, FR;

Jérôme Soquet, Lille, FR;

Eric Van Belle, Lille, FR;

Bart Staels, Lille, FR;

Annabelle Dupont, Lille, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61L 27/54 (2006.01); A61K 31/196 (2006.01); A61K 31/203 (2006.01); A61L 27/18 (2006.01);
U.S. Cl.
CPC ...
A61L 27/54 (2013.01); A61K 31/196 (2013.01); A61K 31/203 (2013.01); A61L 27/18 (2013.01); A61L 2300/21 (2013.01); A61L 2400/02 (2013.01); A61L 2430/20 (2013.01);
Abstract

Aortic valve calcification is a condition in which calcium deposits form on the aortic valve in the heart. These deposits can cause narrowing at the opening of the aortic valve. This narrowing can become severe enough to reduce blood flow through the aortic valve—a condition called aortic valve stenosis. The inventors have shown that retinoic acid decreases calcification and osteoblast-like phenotype in valvular interstitial cells (VICs). More particularly, RARα activation reduces calcification and osteoblast-like phenotype in VIC. On the contrary, ALDH1A1 inhibition increases calcification and osteoblast-like phenotype in VIC. Thus the results prompt to consider that use or retinoic acid receptor (RAR) agonists would be suitable for the reversing, preventing or delaying calcification of the aortic valve.


Find Patent Forward Citations

Loading…